Dr. Saroja D. Rampertab, MD

Dr. Rampertab practices at UF Health Shands Hospital in Gainesville, Florida, part of UF Health.

Dr. Rampertab's NPI, 1215995451, was assigned on May 3, 2006. Dr. Rampertab graduated from Vagelos College of Physicians and Surgeons in 1998. Dr. Rampertab holds Florida license ME120250.

Dr. Rampertab's primary practice is UF Health Shands Hospital, at 1600 SW Archer Rd, Gainesville, FL 32610 in Alachua County. The practice phone is (352) 265-8000.

Dr. Rampertab's primary practice is UF Health Shands Hospital in Gainesville, Florida, part of UF Health. The medical group on file is UF Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rampertab practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Rampertab's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Rampertab is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Rampertab's licenses on file in 4 states: Florida, New Jersey, Pennsylvania and New York.

Dmand AI lists chronic inflammatory bowel disease (IBD), colonoscopy, gastroenteritis, gastrointestinal bleeding, gastrointestinal inflammation, inflammatory bowel disease (IBD), intestinal or bowel obstruction and upper GI endoscopy among the conditions Dr. Rampertab treats.

CMS data shows 372 Medicare services from Dr. Rampertab across 12 procedure codes in 2024, for 224 Medicare patients. Medicare paid $33,751 for them.

CMS counts 224 Medicare patients who saw Dr. Rampertab in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rampertab's median patient age at 69, with 61% women.

In 2024, Dr. Rampertab wrote 324 Medicare Part D claims for 64 patients. 73% of them were for generic drugs. CMS names the drug for 192 of them, across 12 drugs with 11 or more claims each, at $1,006,678 in total drug cost. In 2023, CMS named 248 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 48 out of 100 for Dr. Rampertab for performance year 2024, reported through an alternative payment model (APM). Dr. Rampertab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rampertab as offering telehealth. CMS counts 20 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Rampertab, more than 50% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Rampertab, published from 2014 to 2024. 2024 was the busiest year, with 2. The most frequent topics are Celiac Disease, Adenocarcinoma and Colitis, Ulcerative. Dr. Rampertab has published most often in Gut. Dr. Rampertab's most frequent co-authors are Peter H.r. Green, MD, Naueen Akbar Chaudhry, MD and Nakechand R. Pooran, MD.

CMS Open Payments shows 7 general payments to Dr. Rampertab from 1 drug or device company in 2023. Food and beverage make up the largest share, 68% of the total. Abbvie Inc. paid the most, $158.

Dr. Rampertab graduated from Vagelos College of Physicians and Surgeons in 1998.

Dr. Rampertab is in network with 16 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.